Moteur de recherche d’entreprises européennes
Financement de l’UE (6 889 033 €) : Nouvelles stratégies de test des perturbateurs endocriniens dans le contexte de la neurotoxicité développementale Hor10/12/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Nouvelles stratégies de test des perturbateurs endocriniens dans le contexte de la neurotoxicité développementale
Clear evidence supports associations between endocrine disrupting chemical (EDC) exposure and impaired neurodevelopment. Yet, current hazard assessment of EDCs does not address developmental neurotoxicity. This is due to lack of scientific knowledge on how endocrine disruption is linked to developmental neurotoxicity (DNT). Thus there is an urgent need for novel testing and screening tools to address ED-induced DNT, based on new scientific knowledge. This calls for rapid advances in basic research as well as in the development of screening and testing tools close to the end-users. ENDpoiNTs will address this need by i) integrating advanced expertise in the EDC and DNT fields, two so far rather independent toxicology communities, and ii) continuous interaction with European and international key stakeholders. By combining state-of-the-art in silico and in vitro tools, innovative experimental designs and technologies, and advanced biostatistics on human epidemiological and biomonitoring data, ENDpoiNTs will 1) Generate the necessary scientific insights on the correlative and causal links between endocrine disruption and DNT; 2) Develop predictive in silico tools for chemical screening using machine learning and combination of evidence; 3) Develop and validate in vitro tools for chemical screening and testing that address sex- and species differences; 4) Develop novel molecular endpoints for existing animal-based test guidelines by integrating in vitro, in vivo, and human omics data with behavioural outcomes; 5) Ensure human relevance by linking experimental and epidemiological evidence; 6) Develop an integrated testing approach based on the developed in silico, in vitro, and in vivo assays and molecular markers; 7) Ensure regulatory relevance by developing strategies for implementation of these tools and endpoints into regulatory frameworks. In this way, ENDpoiNTs will meet the scientific, regulatory, and societal needs for improved hazard and risk assessment of EDCs
| Brunel University London | 112 500 € |
| Centre National de la Recherche Scientifique CNRS | 315 438 € |
| GREEN TOX GmbH | 411 890 € |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 124 973 € |
| Institut du Cerveau et de la Moelle Epiniere | 315 525 € |
| IUF - LEIBNIZ-INSTITUT FUR UMWELTMEDIZINISCHE FORSCHUNG GmbH | 1 071 300 € |
| Karlstads Universitet | 101 677 € |
| Karolinska Institutet | 231 745 € |
| Murdoch Childrens Research Institute Public Company LBG | 0,00 € |
| Museum National d'Histoire Naturelle | 0,00 € |
| STICHTING VU | 926 776 € |
| THE University OF Queensland | 0,00 € |
| Umea Universitet | 198 750 € |
| Universidad Complutense de Madrid | 199 375 € |
| Universita Degli Studi Di Milano | 898 518 € |
| UNIVERSITAT KONSTANZ | 300 000 € |
| UNIVERSITEIT UTRECHT | 632 134 € |
| University OF Melbourne | 0,00 € |
| Uppsala Universitet | 1 048 434 € |
https://cordis.europa.eu/project/id/825759
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.